Outcomes in patients with recurrent/progressive glioblastoma treated with bevacizumab funded by a regional cancer drug fund.
Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
S
S
Dixit
Leeds Teaching Hospitals NHS Trust, St. James's Institute of Oncology, Leeds, UK.
P
P
Hatfield
Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Sheffield, UK.
S
S
Clenton
Leeds Teaching Hospitals NHS Trust, St. James's Institute of Oncology, Leeds, UK.
C
C
Loughrey
Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
M
M
Hingorani
D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D000068258:Bevacizumab; D018450:Disease Progression; D016527:Drug Costs; D005909:Glioblastoma / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000191:economics; D013222:State Medicine / Q000191:economics; D016896:Treatment Outcome; D006113:United Kingdom
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab